In a congenic mouse model of AML1-ETO-driven AML, the RARA agonist did not prolong survival, but effected a transient decrease in leukemic burden and a persistent increase in myeloid differentiation [9]. The gene discussed is RARA; the disease is acute myeloid leukemia.